ication was withdrawn because of insufficient effectiveness. Lamotrigine (LTG) was then added to TPM and VPA (LTG 7 50mg/day, TPM 100 mg/day, VPA 900 mg/day).
The EEG showed discontinuous hypsarrhythmia with depressed periods under 30 mV at this time.
At the age of two and a half, the girl was presented at the paediatric ward of our hospital with increased seizure frequency, augmented fatigue, fever and vomiting. On examination the girl appeared moderately ill, but the mother was worried about a significant reduction in alertness and attention. Additionally the seizure frequency was increased up to 20-30 short focal seizures per day. The girl did not take any additional medication than the antiepileptic drugs. Seizure (2007) Summary Valproic acid (VPA) is considered to be a drug of first choice for the therapy of generalized and focal epilepsies, including special epileptic syndromes like the WEST-syndrome. The drug is usually well tolerated; rare serious complications may occur in some patients, including haemorrhagic pancreatitis, coagulapathies, bone marrow suppression, VPA-induced hepatotoxicity and encephalopathy. We report a case of combined appearance of several severe VPA-associated side effects in a two-and a half-year-old girl with lissencephaly. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
The laboratory investigations showed changes in transaminases, lipase, white blood count (WBC), platelets and coagulation parameters. Additionally, we found elevated serum ammonia level and focal temporal slowing (theta-delta activity) in the EEG, in contrast to former EEG findings (shown in Table 1 ). The Serum-VPA level was 87 mg/l.
We immediately stopped the VPA medication and initiated an intravenous carnitine therapy (100 mg/ kg/BW). When signs of hepatotoxicity occur, it is decisive to withdraw VPA early and substitute i.v. carnitine immediately. 1 Especially changes in citrullinogenesis or in other steps of the urea cycle within VPA benefit by an early use of carnitin. 2 To exclude an infectious meningitis or encephalitis, a lumbar puncture was performed without any pathological findings. An X-ray of the chest presented pneumonia pronounced on the right lung, intravenous Cefuroxim 100 mg/kg was administered.
In the Course of the next 10 days the medical condition as well as the laboratory findings improved.
The antiepileptic medication was continued with LTG and TPM in unmodified dosages. The focal slowing at the EEG vanished, the seizure frequency remained acceptable and the girl's vigilance normalized.
Conclusion
In most cases, VPA is a well-tolerated antiepileptic drug with high effectiveness in seizure control. Most of the side effects are mild and transient, but there are also rare but severe side effects, especially hepatotoxicity, 3 encephalopathy, 4 coagulation disorders, 5 pancreatitis 6 and bone marrow suppression. 7 In our case of a two-and a half-year-old girl, we found a combination of encephalopathy, bone marrow suppression, hepatopathy and mild pancreatitis, associated with a VPA-therapy, supposedly triggered off by a simultaneous infection.
Interestingly, the girl previously showed a few serious infections in combination with the antiepileptic medication, but never before did severe VPAassociated side effects appear. According to previous publications, VPA-associated side effects vanish rapidly under withdrawal of VPA and intravenous therapy with carnitine. 1 Especially during infections, the physicians should show specific advertence to VPA-associated problems. An overhaul of parameters like blood count, coagulation parameters, transaminases, ammonia and pancreatic enzymes is necessary, the EEG could provide further indices of a VPAassociated encephalopathy.
In case of such side effects, an immediate withdrawal is required and a supportive therapy with intravenous carnitine is necessary.
In consideration of this approach, the side effects vanish and the patients' outcome is proper.
Multiple severe side effects associated with VPA therapy are well known from the fatalities that had occurred in the 1970s and 1980s. Hepatotoxicity and encephalopathy are most focused upon, but many patients had other related disorders.
Pancreatitis was considered to be unrelated to VPA by Dreifuss, 8 but in the meantime we learned that it is common in patients treated with VPA. In the early patients, lipase and amylase were sometimes not even determined, but in some patients pancreatitis was diagnosed only at autopsy. 9 Similarly, the complex influence of VPA on coagulation was not known at the time. Von Willebrand Jürgens factor, ristocetin-Co-factor and factor XIII were never measured in the early patients, blood counts were not focused upon. One of the patients described by Ward, 10 however, reported as a patient with Hepatotoxicity, in fact died from a cerebral haemorrhage related to severe thrombocytopenia with some accompanying hepatoxicity. In this patient, bone marrow suppression and hepatoxicity also co-existing simultaneously.
VPA-associated side effects 555 000-400,000) 41,000/ml 220,000/ml White blood cells (5300-11,300) 3.500/ml 8900/ml Haemoglobin (10.7-12.7); red Blood cells (4.0-4.9) hb 9.6 g/dl, RBC 2.1 Mill./ml hb 12.1 g/dl, RBC 3.88 Mill./ml Quick-ratio (70-130) 47% 92% Plasma-albumin (35-52) 22 g/l 26 g/l
In the past decade, most patients with severe side effects related to VPA survived. As VPA was withdrawn whenever anyone of the possible symptoms occurred, the large majority of the patients had one or two prevailing symptoms such as hepatotoxicity, 3 pancreatitis, 11 coagulation disorder 5 and bone marrow suppression. 7 Our patient is unusual as she reported the various possible side effects in a short period of time. Moreover, all symptoms were reversible, which has not been described in the literature before. The pattern of the simultaneous side effects is remarkable as many different pathophysiological mechanisms are affected at the same time:
-Hepatotoxicity: known or unknown metabolic defect or metabolic abnormalities, breakdown of the energy metabolism, depletion of intracellular CoA. Disruption of membranes with elevation of ASAT and ALAT. Altered synthesis of coagulation factor proteins. -Pancreatitis: altered membranes, possibly due to impaired lipid Peroxidase. -Encephalopathy: with hyperammonemia, but also without hyperammonemia, possible direct influence of VPA on neurotransmitters. -Bone marrow suppression: totally unrelated to the other side effects, may affect some cell lines selectively, i.e. isolated thrombocytopenia, 5 leucopenia, 12 anaemia, 13 or any combination above. This effect could be related to the effects of VPA directly on the activation of genes, but also the inhibition of histone-decarboxylase. It is supposable that the slight reduction of erythrocytes with an increased MCV could be due to the same mechanism.
At this time, we do not understand why most patients never have any side effects related to VPA and why other patients show such a variety of side effects related to different mechanisms.
Our patient emphasizes nevertheless that all possible side effects have to be looked for an individual patient and that they may be totally reversible after withdrawal of VPA. Additionally, if one severe VPA-associated side effect appears, the possibility of an accompanying secondary side effect is considerable.
